Good afternoon. Thank you for joining us today to discuss LifeMD's Q1 fiscal 2021 results for the three months ended March 31st, 2021. Joining us today is the Chairman and Chief Executive Officer of LifeMD, Justin Schreiber, and the company's Chief Financial Officer, Marc Benathen. I'd like to remind everyone that today's call is being hosted by a webcast, and a recording will be made available via the link in today's press release, which is available in the investor relations section of the company's website. Before we conclude today's call, I'll provide some important cautions regarding the forward-looking statements made by management during the call. I'd like to remind everyone that today's call is being recorded and will be made available for webcast replay via instructions in today's press release, which is available in the investor relations section of the company's website. Now I'd like to turn the call over to LifeMD CEO, Justin Schreiber. Please go ahead. Thank you, operator. Good afternoon, everyone. Thanks for joining us today for our first earnings call of 2021. I hope that everyone on the call and their loved ones are safe and hopeful in the new year now that COVID vaccinations have started. As we enter a new phase of the pandemic curve, the management team would like to give thanks to all the frontline workers who have helped us get to this point and who continue to selflessly assist others before themselves. We are now well into the new fiscal year. LifeMD is off to a strong start, both operationally and financially. Having served over 300,000 customers and patients since our inception, we continue to pioneer the future of healthcare, providing greater access to high quality, convenient, and affordable care in 49 states while converting more and more people to the possibilities of telehealth, as evidenced by our growing patient rolls. While the country continues to emerge from the COVID pandemic, which frankly helped accelerate our industry and our business, I am very pleased to report that LifeMD's growth and acceleration show no signs of slowing down. Indeed, demand continues to build to record levels. We sense that a broader tectonic shift is happening that will radically change the way healthcare is delivered to and experienced by millions of Americans. We are excited to be a part of it, and we are committed to our mission of increasing access to healthcare through direct-to-patient telemedicine. LifeMD stands at the vanguard of a healthcare revolution. I can say without hesitation that our explosive growth and strong patient conversion rates to our subscription-based models have done nothing but trend positively in 2021, and our fantastic results stand as evidence of the trend. In the Q1 of 2021, we grew revenue by over 300% as compared to the same year ago period, and up 41% sequentially from the prior quarter. In addition to this phenomenal growth, we've also begun to see the early results of beginning to optimize and scale aggressively by better leveraging our cost structure while planting the seeds for building a leading telehealth business with profitability in mind. In the Q1 of 2021, we saw an approximate 15%-20% improvement in customer acquisition costs versus the prior quarter and record level gross margins exceeding 80%. This, coupled with the fact that 92% of our revenue currently comes from recurring subscriptions, is laying a very strong foundation for predictable growth over the long term, while also paving our pathway to profitability. At LifeMD, our core domain is in technology and marketing, more specifically, our direct response marketing expertise and in our ability to scale businesses on our holistic digital health platform quickly and efficiently. That said, we have a bigger mission in mind, and our primary goal has been to support the new permanence of patient-centric care through telehealth. The global pandemic surely accelerated the mass adoption of telehealth in 2020, and we used that as an opportunity to really entrench our customer base in products and services that have made a positive difference in the lives of our patients. To propel our narrative as pioneers in digital health, we also want to remind investors who are new to our story that LifeMD predates COVID and will endure long past the pandemic's retreat. We have built a platform that has the ability to support tens, if not hundreds, of direct-to-patient telemedicine offerings. In seeing the value of our offerings, our patients are overwhelmingly choosing subscription-based products and services, which have been fueling our significant sequential growth. In fact, for the first time in company history, more than 50% of our telehealth revenue came from the re-billings of already existing patient subscribers. As an industry leader in telehealth customer acquisition, our growth potential remains massive. We are operating in open white space of a nascent industry with a total addressable market of nearly $1 trillion. To get to where we are now, we placed a strong emphasis on a few strategic imperatives that have really transformed LifeMD's potential. First, we have built a robust patient care process via our digital health platform with unlimited expandability across other indications. In the last week of the quarter, we launched Nava MD, a direct-to-patient clinical tele-dermatology services brand for women, which added further diversification to our growing portfolio of companies. Nava MD is our third launch in four years, and we look forward to further developing the brand. In addition, as I have spoken about before, we continue to anticipate launching our namesake LifeMD primary care platform later this summer. We believe this launch, coupled with our very successful current and future condition-specific telemedicine brands, will provide LifeMD with a powerful and differentiated end-to-end direct-to-patient telehealth platform. Second, in order to support our rapid revenue growth and brand expansion, we have strengthened our management team with leadership set to play pivotal roles in managing our growth. This includes rounding out our executive team with the hires of a Chief Digital Officer, a Chief Medical Officer, and Chief Financial Officer. These hires, coupled with the previous hires to our executive team, have given LifeMD a formidable leadership team with significant direct-to-consumer healthcare and regulatory experience in scaling high-growth businesses. In summary, our Q1 of 2021 was not only marked by record top-line performance, it also saw us make significant strides in solidifying the infrastructure, which will enable LifeMD to scale efficiently towards longer-term profitability. With that, I would like to turn the call over to our CFO, Marc Benathen, who will discuss the period's financials. Marc? Thank you, Justin. Good afternoon, everyone. As Justin mentioned, we've had a fantastic start to fiscal 2021 thus far. Our products and services have been well-received, where our patients have overwhelmingly made the active choice of converting their accounts to subscription-based plans, given the high level of service we provide and the recurring maintenance indications we treat. We continue to see strong unit economics with our LTV to CAC ratios on recurring subscriptions at or approaching 2x on a 12-month basis, and the potential to well exceed 3x on a three-year basis. As of the Q1 of 2021, 92% of our revenue is now recurring subscription-based. To get into the quarter's results, revenue in the Q1 of 2021 totaled a record $18.2 million, up 323% as compared to the same comparable year-ago period, and up 41% from the Q4 of 2020. The growth was driven largely by a 349% increase in telehealth net revenues to $13.3 million. Our WorkSimpli subsidiary contributed net revenue of $4.9 million, up 264% from the year-ago quarter. Including $1.3 million in deferred revenue associated with recurring subscriptions, total adjusted revenue on a non-GAAP basis would've been $19.5 million for the Q1 of 2021. Telehealth order volume grew 373% versus the year-ago period, or 41% sequentially, to 164,452 orders. This increase was driven by a 252% increase in new patients, plus strong retention of existing patients. As a result of the significant performance we had in Q1 and our continued momentum, we are raising our full year 2021 revenue guidance to $90 million-$100 million from the previously given guidance of $85 million-$95 million, reflecting annual growth in 2021 of between 141% and 168% versus 2020. As of the current reporting quarter, we are running on an annualized revenue run rate of $72.8 million, calculated by the current reporting period revenues times four. Gross profit in the Q1 increased 403% to $14.9 million, compared to $3 million in the same year-ago quarter. Gross profit as a percentage of revenue in the Q1 of 2020 increased to 82% from 69% in the same year-ago quarter. The increase of 13% in gross profit was principally attributable to lower product costs, growth of our prescription business, and more stringent inventory management. Operating expense in the Q1 of 2021 was $26.8 million, up from $4.7 million in the same year-ago quarter. The increase was primarily due to increases of discretionary growth, selling and marketing expenses of $15.9 million, general and admin expenses of $5.3 million, other operating expenses of $737,000, customer service expenses of $127,000, and development cost of $114,000. The increase in general and admin costs was primarily due to $2.3 million in non-cash stock-based compensation expense. The majority of the stock-based compensation was related to the appointment of several executive team and board members. The increase in operating expense as compared to the year-ago period was associated with investments made to solidify the long-term rapid and scalable growth of LifeMD's infrastructure, which we expect to leverage these costs as the company continues to grow. Our GAAP net loss attributable to common stockholders for the Q1 totaled $11.6 million, or $0.47 per share. This compares to a net loss attributable to common stockholders of $2.4 million, or $0.23 per share, in the Q1 of 2020. Adjusted EPS is a non-GAAP measure, which excludes the $2.3 million in non-cash stock-based compensation expense. This figure totaled a loss of $0.38 per share for the Q1, as compared to a loss of $0.22 per share in the same year-ago period. In addition to stock-based compensation expense, our net loss for the Q1 of 2021 included other non-cash or financing-related charges, such as interest expense of $139,000, combined amortization expenses of $152,000 and financing transaction expense of $126,000. Adjusted EBITDA, a non-GAAP term which factors out these terms, totaled a loss of $8.9 million in the Q1 of 2021. This compares to an adjusted EBITDA loss of $556,000 in the same year-ago quarter. Now turning to our balance sheet. Cash totaled $13.4 million in March 31st, 2021, as compared to $9.2 million at December 31st, 2020. The increase was primarily due to a private placement with net proceeds of $13.5 million in the period completed in February 2021. As mentioned in our press release earlier today, we have started to do significant work to own in on our economics and KPIs, and as a result, on a go-forward basis, have reduced our cash burn by approximately 30% at current revenue levels. We believe our current cash position and available funds provide the company with ample liquidity to meet our current needs and plans for growth. We also continue to make progress in securing additional financing to further augment our balance sheet position. This wraps up our financial results. I'd now like to turn the call back over to Justin. Thanks, Marc. We're off to a really strong start in 2021, but the best is yet to come. We elevated our infrastructure with key executive appointments, continued to optimize and improve our patient acquisition and patient care teams, transitioned over 90% of our patients to recurring subscriptions, launched Nava MD, and laid the infrastructure to support a business poised for multiples of growth. All of this led to, as Marc mentioned earlier, LifeMD raising our current fiscal year 2021 revenue guidance to $90 million-$100 million, reflecting upwards of 168% growth versus 2020. We believe that the platform we've built, supported by more than 150 full-time and contract employees and over five years of technological development, will facilitate aggressive growth and even stronger unit economics in the years to come. Our focus remains on building innovative and differentiated telemedicine brands that improve access to medical treatment. Brands that are condition-specific and allow for equal focus on customer acquisition and, most importantly, the delivery of amazing healthcare. In doing so, we will continue to transform the way affordable and accessible healthcare is delivered to patients. With that, I would like to open the call for Q&A. Thank you. Ladies and gentlemen, if you would like to ask a question today, please signal by pressing star one on your telephone keypad. Please ensure that the mute function on your telephone is switched off to allow your signal to reach our equipment. Again, to ask a question over the telephone, please signal by pressing star one. We'll pause for just a moment to allow everyone an opportunity to signal for questions. We'll take our first question today from David Larsen from BTIG. Please go ahead. Hey, guys. Congratulations on a very good quarter and the increase in the guidance. I was hoping you could just comment on what you're seeing in terms of demand from the overall market. Obviously, there's been a lot of activity in the space. Walmart acquired a telehealth vendor. Amazon has entered into the space. What are you seeing from your own customers in terms of appetite for the cash pay telehealth business? Thanks. Thanks, David. This is Justin. Look, we're having a very strong Q2. Amazon's entrance or supposed entrance or plan to enter condition-specific D2C telemedicine have had no impact on our business. As we've discussed before, we don't believe that they'll have a significant impact long term. We believe that Amazon entering the space further raises the awareness for telemedicine, and we believe we have a differentiated offering that can compete with Amazon or anybody else in the D2C telemedicine world. With regards to Walmart's acquisition of MeMD, that business is very B2B. It does not compete with us at all. I'm sure that Walmart will do everything they can to aggressively grow that business, but we think it will be, for the most part, focused on a small percentage of people that actually visit a Walmart store. Given the kind of opportunity ahead of us in D2C telemedicine, we think that this type of M&A activity just further demonstrates the incredible opportunity for the company and the amount of white space that exists in the space. We're happy to see big companies entering the space and, again, raising the overall awareness of this transformation of how healthcare is delivered. Okay. That's great. Can you maybe give a little more color on the sales and marketing spend, your customer acquisition costs? I like to see that very significant pop in gross margin. Just any more color around that would be very helpful, like longer term expectations for gross margin and expected trends in the sales and marketing in CAC. Thanks. Yeah, this is Marc. Regarding the gross margin, we expect longer term to see gross margins very similar to the gross margins that we produced this quarter. A lot of it was driven by, one, we've seen our prescription business grow pretty significantly, which has a slightly higher gross margin versus the OTC business. Two, we've been managing in our OTC business, our inventory, a lot tighter. Both of those have certainly laddered up to very strong gross margins, which we expect to be able to maintain in the future. Regarding sales and marketing and CAC, as was mentioned by Justin, we saw a reduction. While we don't release our actual physical CAC cost, the absolute number, we did see about a 15%-20% reduction in this quarter over Q4. We've continued to tighten up since then, and since that time have been able to reduce that cost by about another 15%-20% in the Q2 and on a go-forward basis. We're going to continue to see on an absolute dollar basis, figures that are very similar to what you're seeing in Q1 for the remainder of the year, potentially a little bit higher, but only because you would be acquiring substantially more new patients per day. On a cost per acquisition basis, we expect to get another 15%-20% tighter, which is where we are today, and have that continue to flow through the remainder of the year. Longer term, we think as our brands get bigger and bigger, there's naturally economies of scale, and we'll continue to see further reductions in subsequent years to our CACs and obviously improving our LTV CAC ratios. That's very helpful, Marc. Thanks so much. Can you talk a little bit more about the nature of the sales and marketing spend? What is it actually going into? Is it going into television or more sort of online advertisements? Yeah. Mm-hmm. We have a mix of channels. There's a significant amount of digital spend, social, SEO, SEM, obviously there's television and radio. It's pretty broadly spread across those different channels. We've tested a few other more traditional media channels as well, but a lot of it tends to be either media-enabled or digitally-enabled marketing channels with 100% of it really geared towards discretionary patient acquisition growth, to accelerate our growth in the future. With regards to, let's say, a 20% improvement in CAC, how do you actually get to that? Are the advertising costs improving given your scale, or are you shifting more dollars to a lower cost channel? Yeah. It's less about that. We've kind of built our brands, I mean, one, digitally, there's more recognition of our pages, our position's obviously improving. Two, in our earlier days as you know, many of our brands have only so much history. We've done a lot of testing of our various marketing channels, we've been able to refine those tests and really hone in on what works and what doesn't. Those are really the biggest ways that we're getting there. Look, as we get more scale, we'll be able to have more buying scale as well in the future, which hasn't necessarily fully materialized yet, which is why I mentioned that we do expect to see further improvements in subsequent years. Okay, that's great. Just one more from me, and I'll hop into the queue. How is Nava MD tracking? I know you recently launched that, any early signs or any feedback from the market? I'll take that one, David. Yeah, we did recently launch it. We did a kind of soft launch. We were working a little bit more on just bringing on some other opinion leading dermatologists and fine-tuning some of the protocols. The answer to your question is, we've done a lot of different testing and optimization. We're actually seeing patients arrive at the site less expensively than what we're seeing with RexMD or some of our other brands. We, very optimistic there's a great opportunity there, but we're not seeing a lot of revenue right now from that brand. We expect to start to see some more meaningful revenue this quarter. Great. Just one more. What is your retention rate right now? For all of the customers that you're bringing on board, where you're selling them products through telehealth orders, what is your overall retention rate? That's not a figure that we necessarily put out publicly for competitive reasons. As I mentioned, we put out what our directional LTV CACs are. We're seeing on average about a two to one return in the first year. We are retaining a substantial amount of those patients within the first year as you move through. There's a little bit of fall off in the first month. Typically, your first rebill, you'll retain somewhere around 75%-80% of patients. After that, you're looking at single-digit fall off in any subsequent billing period. Once you get to around the fourth or fifth billing period, you're looking at really pretty minimal fall off, if that. Okay. I think 92% of the revenue is subscription-based, is that correct? Yeah, pretty much essentially most, if not all of the business outside of the third-party marketplace sales are subscription-based at this point. Okay, thanks very much. I'll hop into the queue now. Thank you. Thank you. We will now go to our next question from Andrew D'Silva from B. Riley Securities. Please go ahead. Hey, good afternoon. Congrats on the quarter, and thanks for taking my questions. I'm just a little bit curious if you could provide a little bit more granularity on the breakout of expenses as it relates to WorkSimpli and the telehealth business. I'm just trying to get a better understanding of how to model LTV to cash as it relates to telehealth side. Yeah. Without going into the specific line items, when you look at the sales and marketing expense line, which is obviously the largest line in there and what really fuels the growth of the business, roughly about $13.5 million-$14 million of that marketing expense was associated with the telehealth business, and the remainder of that expense roughly was associated with the WorkSimpli business. When you look at a lot of the other expense categories, WorkSimpli is a pretty inexpensive business, as is our telehealth business to run from an infrastructure standpoint. A lot of it has to do around the sales and marketing. I mean, the other lines, there's some payroll and a few other categories, but it's not too significant. Sales and marketing would be the most material area to look at the breakout. Okay. That business did very well both year-over-year and quarter-over-quarter. I'm just curious if that was a one-off. I understand it's a highly subscription-based model, but was there anything one-off that took place that resulted in that growth? Yeah. Strong, similar cadence that we should expect as the year goes on? Yeah. Obviously, you're not going to see a doubling every single quarter as the business gets bigger, but you should expect to continue to see very significant growth in that business. A lot of it has to do with they're starting to hit critical mass. There were some early technical issues and marketing optimizations that had to take place, and those are all behind us at this point. The business has a lot of very predictable and tremendous growth and you should continue to expect to see that materialize throughout the year. Okay. Good. Moving back over to telehealth side of the business. Obviously, we're getting close to critical mass in both the hair and men's health. I was curious if there were any sort of tuck-ins or bolt-ons that you're seeing out there that make sense for either of those brands or any of the upcoming brands. Things like patient monitoring initiatives and stuff like that seem to be very relevant, particularly given the differentiated platform you're developing. Yeah, Andy, I'll take that one. We're looking at a lot of different inorganic opportunities, and we haven't looked at anything. We're pretty familiar with the patient monitoring space. We haven't done a lot of work in that space, and that's not somewhere where I see us doing something in the near term. We're seeing new opportunities, probably wouldn't be accurate to say on a daily basis, but certainly we're seeing, at least on a weekly basis, interesting opportunities in the traditional healthcare product world. Even in the proprietary over-the-counter world as well, right? Just stuff that could be very synergistic with our current offerings. Look, as we said previously, we're going to be very aggressive and pursue those that make sense and continue to drive unit economics and revenue growth across the business. Okay. Last question for me is just related to the subscription prescription style model that you're building. How much of the benefit that you saw in the Q1 would you attribute to things like the compounding proprietary products that you've been introducing recently? If those have been fruitful or are you having any other new launches related to proprietary, either compounded or OTC products coming out with any of the brands soon? We're seeing some progress with the compounded hair loss products. Not as much as we would've liked to. There's a simple reason for that. We've just been aggressively expanding our infrastructure and bandwidth across the business. Our telemedicine business has been growing, and especially our Men's Health RexMD line has been growing so aggressively that unfortunately we're still a company that has to decide where we're going to kind of focus bandwidth. We've hired a lot of people from creative people to developers, project managers, brand managers. We have a lot of energy right now focused on both Nava and on this telemedicine business and compounded topical drug business within the Shapiro MD brand. As I said earlier to Dave, we believe that we're going to start to really see very strong traction with both of those. Okay, great. Thank you very much. Best of luck going forward. Thanks, Andy. Thank you. That will conclude today's question and answer session. I would now like to turn the conference back over to Justin Schreiber for any additional or closing remarks. I'd just like to say thank you to all of our shareholders and all of our employees who have been supportive, especially over the rather tumultuous 30 days we've been through. Like I said in the beginning of the call, this company has an extremely bright future, and I really look forward to continuing to keep everybody updated. Future calls like this. Appreciate all your support and have a great evening. Thank you. Before we conclude today's call, I would like to provide the company's Safe Harbor statements that include important cautions regarding forward-looking statements made during today's call. The information that the company has provided in this conference call includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the company's plans, strategies, and prospects, both business and financial. While the company believes that its plans, intentions, and expectations that are reflected in or suggested by these forward-looking statements are reasonable, the company cannot assure you that it will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Many of the forward-looking statements made during this conference call may be identified by the use of forward-looking words such as believe, expect, anticipate, should, planned, will, may, intend, estimated, and potential, among others. Important factors that could cause actual results to differ materially from the forward-looking statements made during this conference call include market conditions and those set forth in reports or documents that the company files from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to LifeMD, Inc. or a person acting on behalf are expressly qualified in their entirety by this cautionary language. Before we end today's conference call, I would like to remind everyone that this call will be available for replay starting later this evening. Please refer to today's earnings release for the replay instructions available via the company's website at www.lifemd.com. Thank you for joining us today, and this concludes the conference call. You may now disconnect.